Marvel Biosciences Announces Grant of Deferred Share Units

Calgary, Alberta, Canada, November 18, 2026 - Marvel Biosciences Corp. (TSX-V: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), announces the award of 59,693 deferred share units (“DSUs”) to Marvel’s three independent directors, in lieu of cash payment for directors’ fees. The DSUs will all vest on November 18, 2027.  Vested DSUs shall be...

Marvel Announces Final Shank3 Data: MB-204 Highly Effective at Reversing Autism Behaviours

Calgary, Alberta – November 10, 2026 – Marvel Biosciences Corp. (TSXV: MRVL | OTCQB: MBCOF), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), a drug discovery company developing novel therapeutics for autism spectrum disorder (“ASD”) and related neurodevelopmental disorders, is pleased to share part of the preliminary data set from its...

Marvel Biosciences Advances MB-204 Toward First-in Human Testing, Selects CMAX as Phase I Clinical Trial Site

Calgary, Alberta – October 19, 2026 – Marvel Biosciences Corp. (TSXV: MRVL | OTCQB: MBCOF), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), a drug discovery company developing novel therapeutics for autism spectrum disorder (“ASD”) and related neurodevelopmental disorders, is pleased to announce that it has selected CMAX as the Phase I...

Marvel Biosciences Reports MB-204 as Highly Effective at Treating Autism Behaviours in Shank3 Mouse Model

Calgary, Alberta – October 8, 2026 – Marvel Biosciences Corp. (TSXV: MRVL | OTCQB: MBCOF), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), a drug discovery company developing novel therapeutics for autism spectrum disorder (“ASD”) and related neurodevelopmental disorders, is pleased to announce preliminary results from its preclinical study of...

Marvel Biosciences Signs Letter of Intent with Novatech for Phase 1 Trial of MB-204 and Provides Corporate Update

Calgary, Alberta – October 6, 2026 – Marvel Biosciences Corp. (TSXV: MRVL | OTCQB: MBCOF), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), a drug discovery company developing novel therapeutics for autism spectrum disorder (“ASD”) and related neurodevelopmental disorders, is pleased to announce it has signed a letter of intent with Novatech,...

Marvel Biosciences Fait Le Point Sur Un Placement Privé Pouvant Atteindre 3 Millions De Dollars

Calgary (Alberta), 17 septembre 2026 – Marvel Biosciences Corp. (TSXV : MRVL; OTCQB : MBCOF) (« Marvel » ou la « Société ») a annoncé aujourd’hui que, à la suite de ses communiqués de presse des 16 juillet 2026, 19 août 2026 et 9 septembre 2026, elle entend réaliser un placement privé sans courtier (le « Placement ») d’unités de la Société (les « Unités ») au prix de 0,15 $ par Unité. Le...

Marvel Biosciences Provides Update on Private Placement for up to $3.0 Million

Calgary, Alberta ‐ September 17, 2026 ‐ Marvel Biosciences Corp. (TSXV: MRVL OTCQB: MBCOF) ("Marvel" or the "Company") announced today that, further to its July 16, 2026, August 19, 2026 and September 9, 2026 press releases, it intends to complete a non‐brokered private placement offering (the “Offering”) of units of the Company (“Units”) at a price of $0.15 per Unit.  The Offering will be for a...

Marvel Biosciences Annonce la Prolongation de la Date Limite de Clôture du Placement Privé

Ne pas distribuer aux services de presse américains ni diffuser aux États-Unis Calgary (Alberta), 9 septembre 2026– Marvel Biosciences Corp. (TSXV : MRVL; OTCQB : MBCOF) (« Marvel » ou la « Société ») annonce avoir obtenu l’approbation de la Bourse de croissance TSX (« TSXV ») afin de prolonger la date limite de clôture de son placement privé annoncé précédemment (voir les communiqués de presse...

Marvel Biosciences Announces Extension to Closing Date of Private Placement

Calgary, Alberta ‐ September 9, 2026 ‐ Marvel Biosciences Corp. (TSXV: MRVL OTCQB: MBCOF) ("Marvel" or the "Company") announces that it has received approval from the TSX Venture Exchange (“TSXV”) to extend the closing deadline of its previously announced private placement (see July 16, 2026 and August 19, 2026 press releases) (the “Offering”). The deadline by which the Company must file its...

Marvel Biosciences Announces Grant of Deferred Share Units

Calgary, Alberta, Canada, September 1, 2026 - Marvel Biosciences Corp. (TSX-V: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), announces the award of 50,001 deferred share units (“DSUs”) to Marvel’s three independent directors, in lieu of cash payment for directors’ fees. The DSUs will all vest on September 1, 2027.  Vested DSUs shall be...